MXPA02012897A - Combinaciones de bisfosfonatos, agentes estrigenicos y opcionalmente estrogenos. - Google Patents
Combinaciones de bisfosfonatos, agentes estrigenicos y opcionalmente estrogenos.Info
- Publication number
- MXPA02012897A MXPA02012897A MXPA02012897A MXPA02012897A MXPA02012897A MX PA02012897 A MXPA02012897 A MX PA02012897A MX PA02012897 A MXPA02012897 A MX PA02012897A MX PA02012897 A MXPA02012897 A MX PA02012897A MX PA02012897 A MXPA02012897 A MX PA02012897A
- Authority
- MX
- Mexico
- Prior art keywords
- bisphosphonates
- combinations
- estrogenic agents
- estrogens
- optionally
- Prior art date
Links
- 239000000262 estrogen Substances 0.000 title 2
- 229940122361 Bisphosphonate Drugs 0.000 title 1
- 150000004663 bisphosphonates Chemical class 0.000 title 1
- 229940011871 estrogen Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21606900P | 2000-07-06 | 2000-07-06 | |
| US21618800P | 2000-07-06 | 2000-07-06 | |
| PCT/US2001/020970 WO2002003976A2 (fr) | 2000-07-06 | 2001-06-29 | Combinaisons de bisphosphonates, de substances a action oestrogenique et eventuellement d'oestrogenes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02012897A true MXPA02012897A (es) | 2003-10-24 |
Family
ID=26910620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02012897A MXPA02012897A (es) | 2000-07-06 | 2001-06-29 | Combinaciones de bisfosfonatos, agentes estrigenicos y opcionalmente estrogenos. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1299093A2 (fr) |
| JP (1) | JP2004502730A (fr) |
| CN (1) | CN1450913A (fr) |
| AU (1) | AU2001273125A1 (fr) |
| BR (1) | BR0112364A (fr) |
| CA (1) | CA2415052A1 (fr) |
| MX (1) | MXPA02012897A (fr) |
| WO (1) | WO2002003976A2 (fr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6376486B1 (en) | 2000-07-06 | 2002-04-23 | American Home Products Corporation | Methods of inhibiting sphincter incontinence |
| WO2002003989A2 (fr) * | 2000-07-06 | 2002-01-17 | Wyeth | Therapie permettant d'inhiber l'incontinence du sphincter |
| US6455568B2 (en) | 2000-07-06 | 2002-09-24 | Wyeth | Combination therapy for inhibiting sphincter incontinence |
| JP2006504409A (ja) | 2002-07-24 | 2006-02-09 | チルドレンズ ホスピタル メディカル センター | 鏡像異性のエクオールを含有する組成物および製品、およびその製造方法 |
| US8668914B2 (en) | 2002-07-24 | 2014-03-11 | Brigham Young University | Use of equol for treating skin diseases |
| US8580846B2 (en) | 2002-10-29 | 2013-11-12 | Brigham Young University | Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders |
| AU2003286781B2 (en) | 2002-10-29 | 2009-05-21 | Brigham Young University | Use of equol for treating androgen mediated diseases |
| CN1649598B (zh) | 2002-12-20 | 2011-12-07 | 弗·哈夫曼-拉罗切有限公司 | 高剂量伊班膦酸制剂 |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| BR112018006121B1 (pt) | 2015-10-01 | 2024-01-23 | Olema Pharmaceuticals, Inc | COMPOSTOS DE TETRA-HIDRO-1H-PIRIDO[3,4-b]INDOL, COMPOSIÇÕES COMPREENDENDO OS REFERIDOS COMPOSTOS E USOS DOS MESMOS |
| HRP20221462T1 (hr) | 2015-12-09 | 2023-01-20 | The Board Of Trustees Of The University Of Illinois | Selektivni nishodni regulatori receptora estrogena na bazi benzotiofena |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| EP3455218A4 (fr) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | Dégronimères de type glutarimide liés au carbone c3 pour la dégradation de protéines cibles |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| EP3455219A4 (fr) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | Dégronimères de c3-glutarimide liés à une amine pour la dégradation de protéines cibles |
| MX2019000200A (es) | 2016-07-01 | 2019-09-26 | G1 Therapeutics Inc | Agentes antiproliferativos basados en pirimidina. |
| WO2018081168A2 (fr) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Répresseurs du récepteur oestrogénique sélectifs mixtes à base de benzothiophène |
| EP3565558B1 (fr) | 2017-01-06 | 2023-12-06 | G1 Therapeutics, Inc. | Polythérapie avec un composé serd et un inhibiteur cdk4/6 pour le traitement du cancer |
| TW201835064A (zh) | 2017-02-10 | 2018-10-01 | 美商G1治療公司 | 苯并噻吩雌激素受體調節劑 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| EP3645001B1 (fr) | 2017-06-29 | 2024-07-03 | G1 Therapeutics, Inc. | Formes morphiques de git38 et leurs procédés de fabrication |
| EP3897631A4 (fr) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | Dégradation ciblée de protéines |
| WO2021007146A1 (fr) | 2019-07-07 | 2021-01-14 | Olema Pharmaceuticals, Inc. | Régimes d'antagonistes du récepteur des oestrogènes |
| PE20221724A1 (es) | 2019-12-20 | 2022-11-04 | C4 Therapeutics Inc | Compuestos de isoindolinona e indazol para la degradacion del receptor del factor de crecimiento epidermico (egfr) |
| KR20220166797A (ko) | 2020-03-05 | 2022-12-19 | 씨4 테라퓨틱스, 인코포레이티드 | Brd9의 표적화된 분해를 위한 화합물 |
| IL300397A (en) | 2020-08-05 | 2023-04-01 | C4 Therapeutics Inc | Compounds for targeted knockdown of RET |
| EP4565585A1 (fr) | 2022-08-03 | 2025-06-11 | Bristol-Myers Squibb Company | Composés pour moduler la protéine ret |
| KR20250116017A (ko) | 2022-11-04 | 2025-07-31 | 브리스톨-마이어스 스큅 컴퍼니 | Ret-ldd 단백질 억제제 |
| WO2024097989A1 (fr) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Agents de dégradation de protéine ret-ldd |
| WO2025006753A2 (fr) | 2023-06-30 | 2025-01-02 | Merck Patent Gmbh | Composés hétérobifonctionnels pour la dégradation de la protéine kras |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3894299A (en) * | 1998-05-15 | 1999-12-06 | American Home Products Corporation | Compositions comprising 2-phenyl-indole compounds and estrogen formulations |
| GEP20033079B (en) * | 1998-05-15 | 2003-10-27 | Wyeth Corp | Pharmaceutical Compositions for Treatment of Diseases Caused by Estrogens Deficiency |
| US6465445B1 (en) * | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
-
2001
- 2001-06-29 MX MXPA02012897A patent/MXPA02012897A/es unknown
- 2001-06-29 CA CA002415052A patent/CA2415052A1/fr not_active Abandoned
- 2001-06-29 WO PCT/US2001/020970 patent/WO2002003976A2/fr not_active Application Discontinuation
- 2001-06-29 JP JP2002508431A patent/JP2004502730A/ja active Pending
- 2001-06-29 EP EP01952365A patent/EP1299093A2/fr not_active Withdrawn
- 2001-06-29 AU AU2001273125A patent/AU2001273125A1/en not_active Abandoned
- 2001-06-29 CN CN01815091A patent/CN1450913A/zh active Pending
- 2001-06-29 BR BR0112364-5A patent/BR0112364A/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR0112364A (pt) | 2003-07-29 |
| EP1299093A2 (fr) | 2003-04-09 |
| WO2002003976A3 (fr) | 2003-01-03 |
| AU2001273125A1 (en) | 2002-01-21 |
| WO2002003976A2 (fr) | 2002-01-17 |
| JP2004502730A (ja) | 2004-01-29 |
| CA2415052A1 (fr) | 2002-01-17 |
| CN1450913A (zh) | 2003-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA02012897A (es) | Combinaciones de bisfosfonatos, agentes estrigenicos y opcionalmente estrogenos. | |
| MXPA02012896A (es) | Combinaciones de estatinas, agentes estrogenicos y opcionalmente estrogenos. | |
| MXPA02012891A (es) | Composiciones farmaceuticas de agentes estrogenicos. | |
| AP2002002659A0 (en) | 3-Nitrogen-6,7-dioxygen steroids and uses related thereto | |
| MXPA03000183A (es) | Agentes anti-inflamatorios de glucocorticoide-selectivos. | |
| ZA200204165B (en) | Fulvestrant formulation. | |
| GB2381456B (en) | An anhydrofructose derived antimicrobial agent | |
| MXPA03002410A (es) | 4-amino-quinazolinas. | |
| GB2375930B (en) | Private wireless WAP system | |
| HUP0400646A3 (en) | Steroid hormone-compositions and processes for their preparation | |
| MXPA03001983A (es) | Exemestano como agente quimiopreventivo. | |
| MXPA03003522A (es) | Panal. | |
| MXPA03005568A (es) | Composicion herbicida. | |
| EG23262A (en) | Delta -pyrrolines. | |
| MXPA03001591A (es) | Derivados y analogos de 10-aril-11-h-benzo(b) fluorena para uso medicinal. | |
| MXPA03001877A (es) | 2-guanidin-4-arilquinazolinas. | |
| IL144455A0 (en) | 16-hydroxyestratrienes as selective estrogens | |
| MXPA03002668A (es) | Guanidinas de sulfonilo. | |
| MXPA03002411A (es) | 4-amino-quinazolinas. | |
| GB0316320D0 (en) | Remedies for dermatophytosis | |
| MXPA03005494A (es) | Benzoilpiridazinas. | |
| MXPA03002521A (es) | Triazol-epotilona. | |
| ZA200300417B (en) | 16alpha-methyl or ethyl substituted estrogens. | |
| SI1272504T1 (sl) | 8beta-hidrokarbilno substituirani estratrieni kotestrogeni s selektivnim učinkom | |
| EP1291461A4 (fr) | Recuperateur de couleur |